Research - Melbourne, Victoria, Australia
Aravax is a clinical stage biotechnology company developing a novel peptide-based immunotherapy, PVX108, for the treatment of peanut allergy. Aravax is striving to improve the lives of patients living with peanut allergies by developing a therapy that precisely targets the underlying cause of disease, bringing benefits in safety and convenience.
DoubleClick
Outlook
Varnish
Google Tag Manager
Facebook Login (Connect)
Mobile Friendly